Inhibrx Biosciences Key Executives
This section highlights Inhibrx Biosciences's key executives, including their titles and compensation details.
Find Contacts at Inhibrx Biosciences
(Showing 0 of )
Inhibrx Biosciences Earnings
This section highlights Inhibrx Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
$14.09
Stock Price
$203.97M
Market Cap
172
Employees
La Jolla, CA
Location
Financial Statements
Access annual & quarterly financial statements for Inhibrx Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $200.00K | $1.80M | $2.18M | $7.12M | $12.81M |
| Cost of Revenue | $- | $1.19M | $2.85M | $2.69M | $73.50M |
| Gross Profit | $200.00K | $609.00K | $-668.00K | $4.44M | $-60.69M |
| Gross Profit Ratio | 100.00% | 33.83% | -30.67% | 62.30% | -473.82% |
| Research and Development Expenses | $203.74M | $190.65M | $110.19M | $71.44M | $73.50M |
| General and Administrative Expenses | $127.91M | $29.38M | $21.12M | $12.36M | $6.84M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $127.91M | $29.38M | $21.12M | $12.36M | $6.84M |
| Other Expenses | $- | $- | $-14.00K | $-106.00K | $-80.00K |
| Operating Expenses | $331.65M | $219.83M | $131.29M | $83.69M | $80.25M |
| Cost and Expenses | $331.65M | $221.02M | $131.29M | $83.69M | $80.25M |
| Interest Income | $10.94M | $11.92M | $16.11M | $5.22M | $10.82M |
| Interest Expense | $13.49M | $31.84M | $16.11M | $5.22M | $10.82M |
| Depreciation and Amortization | $2.29M | $1.19M | $1.23M | $2.69M | $2.39M |
| EBITDA | $1.70B | $-206.69M | $-125.82M | $-76.56M | $-67.44M |
| EBITDA Ratio | 851675.00% | -11482.94% | -5928.24% | -1074.58% | -526.57% |
| Operating Income | $-331.45M | $-219.22M | $-129.12M | $-76.56M | $-67.44M |
| Operating Income Ratio | -165724.00% | -12178.94% | -5928.24% | -1074.58% | -526.57% |
| Total Other Income Expenses Net | $2.02B | $-20.50M | $-29.90M | $-5.20M | $-8.19M |
| Income Before Tax | $1.69B | $-239.72M | $-145.22M | $-81.77M | $-75.63M |
| Income Before Tax Ratio | 843787.00% | -13318.00% | -6667.72% | -1147.59% | -590.52% |
| Income Tax Expense | $2.00K | $3.00K | $3.00K | $2.00K | $3.00K |
| Net Income | $1.69B | $-241.36M | $-145.23M | $-81.77M | $-75.64M |
| Net Income Ratio | 843786.00% | -13408.94% | -6667.86% | -1147.62% | -590.54% |
| EPS | $114.01 | $-5.12 | $-3.62 | $-2.15 | $-2.99 |
| EPS Diluted | $112.62 | $-5.12 | $-3.62 | $-2.15 | $-2.99 |
| Weighted Average Shares Outstanding | 14.80M | 47.13M | 40.11M | 38.01M | 25.26M |
| Weighted Average Shares Outstanding Diluted | 14.98M | 47.13M | 40.11M | 38.01M | 25.26M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.00K | $- | $100.00K | $- | $1.63M | $119.00K | $30.00K | $17.00K | $274.00K | $278.00K | $711.00K | $915.00K | $2.84M | $2.51M | $918.00K | $863.00K | $2.78M | $5.83M | $3.33M | $872.00K |
| Cost of Revenue | $- | $- | $475.00K | $360.00K | $298.00K | $304.00K | $731.00K | $722.00K | $720.00K | $719.00K | $29.91M | $- | $- | $- | $- | $16.44M | $- | $19.84M | $18.97M | $- |
| Gross Profit | $100.00K | $- | $-375.00K | $-360.00K | $1.34M | $-185.00K | $-701.00K | $-705.00K | $-446.00K | $-441.00K | $-29.20M | $915.00K | $2.84M | $2.51M | $918.00K | $-15.57M | $2.78M | $-14.01M | $-15.64M | $872.00K |
| Gross Profit Ratio | 100.00% | 0.00% | -375.00% | 0.00% | 81.80% | -155.50% | -2336.70% | -4147.10% | -162.80% | -158.60% | -4106.20% | 100.00% | 100.00% | 100.00% | 100.00% | -1804.80% | 100.00% | 101.29% | 100.15% | 100.00% |
| Research and Development Expenses | $33.37M | $38.89M | $67.63M | $63.59M | $81.84M | $38.06M | $34.11M | $37.39M | $30.45M | $24.93M | $29.91M | $24.89M | $18.61M | $18.48M | $17.90M | $16.44M | $17.67M | $19.84M | $18.97M | $17.02M |
| General and Administrative Expenses | $16.66M | $7.90M | $93.37M | $9.97M | $7.83M | $7.89M | $7.26M | $6.40M | $5.32M | $5.35M | $5.40M | $5.05M | $3.65M | $2.85M | $2.85M | $3.01M | $2.21M | $1.62M | $1.53M | $1.47M |
| Selling and Marketing Expenses | $- | $- | $- | $-104.00K | $-46.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $16.66M | $7.90M | $93.37M | $9.87M | $7.79M | $7.89M | $7.26M | $6.40M | $5.32M | $5.35M | $5.40M | $5.05M | $3.65M | $2.85M | $2.85M | $3.01M | $2.21M | $1.62M | $1.53M | $1.47M |
| Other Expenses | $- | $- | $- | $-59.00K | $-158.00K | $-5.96M | $-217.00K | $-5.15M | $-5.42M | $-5.32M | $17.00K | $-14.00K | $-1.78M | $-1.00K | $5.00K | $16.00K | $-539.00K | $-4.45M | $-5.00K | $10.00K |
| Operating Expenses | $50.03M | $46.80M | $161.00M | $73.47M | $89.62M | $45.95M | $41.37M | $43.78M | $35.77M | $30.28M | $35.31M | $29.93M | $22.24M | $21.31M | $20.72M | $19.42M | $19.88M | $21.38M | $20.50M | $18.48M |
| Cost and Expenses | $50.03M | $46.80M | $161.00M | $73.83M | $89.92M | $45.95M | $41.37M | $43.78M | $35.77M | $30.28M | $35.31M | $29.93M | $22.24M | $21.31M | $20.72M | $19.42M | $19.88M | $21.38M | $20.50M | $18.48M |
| Interest Income | $2.00M | $2.89M | $2.74M | $3.30M | $4.70M | $2.32M | $2.41M | $5.08M | $5.34M | $5.34M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $5.36M | $8.13M | $8.22M | $8.15M | $7.91M | $5.08M | $5.34M | $5.34M | $3.15M | $2.27M | $1.78M | $1.78M | $914.00K | $745.00K | $532.00K | $4.43M | $3.40M | $2.45M |
| Depreciation and Amortization | $689.00K | $760.00K | $476.00K | $360.00K | $298.00K | $304.00K | $731.00K | $295.00K | $720.00K | $719.00K | $324.00K | $344.00K | $307.00K | $299.00K | $298.00K | $291.00K | $265.00K | $249.00K | $249.00K | $256.00K |
| EBITDA | $-47.18M | $-43.10M | $1.86B | $-73.47M | $-87.99M | $-43.33M | $-38.85M | $-41.06M | $-35.50M | $-30.00M | $-34.27M | $-28.67M | $-19.40M | $-18.50M | $-19.50M | $-18.25M | $-17.11M | $-15.56M | $-16.92M | $-17.34M |
| EBITDA Ratio | -47176.00% | 0.00% | 1863800.00% | 0.00% | -5385.01% | -38510.08% | -129493.33% | -257447.06% | -12956.20% | -10792.45% | -4820.39% | -3133.66% | -684.20% | -737.76% | -2123.97% | -2114.83% | -616.25% | -267.04% | -507.59% | -1989.11% |
| Operating Income | $-49.93M | $-46.80M | $-160.90M | $-73.83M | $-88.29M | $-45.83M | $-41.34M | $-43.77M | $-35.50M | $-30.00M | $-34.60M | $-29.02M | $-19.40M | $-18.80M | $-19.80M | $-18.56M | $-17.11M | $-15.56M | $-17.17M | $-17.61M |
| Operating Income Ratio | -49928.00% | 0.00% | -160898.00% | 0.00% | -5403.24% | -38510.08% | -137796.67% | -257447.06% | -12956.20% | -10792.45% | -4865.96% | -3171.26% | -684.20% | -749.64% | -2156.97% | -2150.41% | -616.25% | -267.04% | -514.91% | -2019.61% |
| Total Other Income Expenses Net | $2.06M | $2.93M | $2.02B | $-4.88M | $-3.69M | $-5.96M | $-5.71M | $-5.15M | $-5.42M | $-5.32M | $-3.13M | $-2.24M | $-1.78M | $-1.78M | $-909.00K | $-729.00K | $-539.00K | $-4.45M | $-718.00K | $-2.48M |
| Income Before Tax | $-47.87M | $-43.86M | $1.86B | $-78.71M | $-91.97M | $-51.79M | $-47.05M | $-48.92M | $-40.92M | $-35.33M | $-37.73M | $-31.25M | $-21.19M | $-20.58M | $-20.71M | $-19.29M | $-17.65M | $-20.01M | $-17.89M | $-20.09M |
| Income Before Tax Ratio | -47865.00% | 0.00% | 1858000.00% | 0.00% | -5628.76% | -43518.49% | -156823.33% | -287741.18% | -14932.85% | -12706.83% | -5306.33% | -3415.74% | -747.14% | -820.57% | -2255.99% | -2234.88% | -635.66% | -343.46% | -536.44% | -2304.24% |
| Income Tax Expense | $- | $- | $2.00K | $316.72K | $-4.00K | $2.00K | $5.00K | $-225.00K | $-1.00K | $5.32M | $4.00K | $2.24M | $-307.00K | $1.78M | $919.00K | $2.00K | $3.00K | $487.00K | $3.40M | $2.46M |
| Net Income | $-47.87M | $-43.86M | $1.86B | $-78.71M | $-93.60M | $-51.79M | $-47.05M | $-48.69M | $-40.91M | $-40.65M | $-37.73M | $-33.49M | $-21.19M | $-20.58M | $-20.71M | $-19.29M | $-17.65M | $-20.50M | $-17.89M | $-20.09M |
| Net Income Ratio | -47865.00% | 0.00% | 1858000.00% | 0.00% | -5728.52% | -43520.17% | -156840.00% | -286417.65% | -14932.48% | -14621.22% | -5306.89% | -3660.22% | -747.14% | -820.57% | -2255.99% | -2235.11% | -635.77% | -351.82% | -536.44% | -2304.24% |
| EPS | $-3.23 | $-2.84 | $128.35 | $-1.44 | $-1.73 | $-1.10 | $-1.08 | $-1.12 | $-0.95 | $-1.04 | $-0.97 | $-0.86 | $-0.55 | $-0.54 | $-0.55 | $-0.51 | $-0.47 | $-0.77 | $-0.50 | $-0.70 |
| EPS Diluted | $-3.19 | $-2.84 | $125.48 | $-1.44 | $-1.73 | $-1.10 | $-1.08 | $-1.12 | $-0.95 | $-1.04 | $-0.97 | $-0.86 | $-0.55 | $-0.54 | $-0.55 | $-0.51 | $-0.47 | $-0.77 | $-0.50 | $-0.70 |
| Weighted Average Shares Outstanding | 14.80M | 15.47M | 14.48M | 54.55M | 54.03M | 47.15M | 43.64M | 43.58M | 43.27M | 39.07M | 39.04M | 39.02M | 38.58M | 37.89M | 37.82M | 37.74M | 37.71M | 26.75M | 35.65M | 28.79M |
| Weighted Average Shares Outstanding Diluted | 14.98M | 15.47M | 14.81M | 54.55M | 54.03M | 47.15M | 43.64M | 43.58M | 43.27M | 39.07M | 39.04M | 39.02M | 38.58M | 37.89M | 37.82M | 37.74M | 37.71M | 26.75M | 35.65M | 28.79M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $152.60M | $277.92M | $273.87M | $131.30M | $128.66M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $152.60M | $277.92M | $273.87M | $131.30M | $128.66M |
| Net Receivables | $397.00K | $778.00K | $257.00K | $878.00K | $615.00K |
| Inventory | $- | $- | $-257.00K | $-878.00K | $-129.28M |
| Other Current Assets | $7.41M | $16.66M | $5.51M | $7.81M | $132.17M |
| Total Current Assets | $160.40M | $295.36M | $280.49M | $139.11M | $132.17M |
| Property Plant Equipment Net | $13.54M | $9.37M | $7.22M | $9.49M | $11.32M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.83M | $3.16M | $3.16M | $1.85M | $245.00K |
| Total Non-Current Assets | $20.37M | $12.54M | $10.38M | $11.34M | $11.57M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $180.77M | $307.89M | $290.88M | $150.45M | $143.74M |
| Account Payables | $9.24M | $8.31M | $4.34M | $9.12M | $13.46M |
| Short Term Debt | $1.59M | $4.13M | $3.72M | $1.67M | $1.50M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $166.00K | $2.03M | $3.08M |
| Other Current Liabilities | $29.89M | $43.88M | $19.35M | $9.62M | $13.36M |
| Total Current Liabilities | $40.73M | $56.31M | $27.58M | $22.45M | $31.40M |
| Long Term Debt | $6.45M | $208.08M | $205.24M | $70.47M | $35.95M |
| Deferred Revenue Non-Current | $- | $- | $- | $110.00K | $737.00K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-110.00K | $- |
| Other Non-Current Liabilities | $- | $- | $- | $5.14M | $180.00K |
| Total Non-Current Liabilities | $6.45M | $208.08M | $205.24M | $75.61M | $36.87M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $47.18M | $264.39M | $232.82M | $98.07M | $68.27M |
| Preferred Stock | $- | $- | $- | $150.45M | $143.74M |
| Common Stock | $1.00K | $5.00K | $4.00K | $4.00K | $4.00K |
| Retained Earnings | $-106.13M | $-613.73M | $-372.37M | $-227.15M | $-145.38M |
| Accumulated Other Comprehensive Income Loss | $- | $0 | $- | $-150.45M | $-143.74M |
| Other Total Stockholders Equity | $239.72M | $657.23M | $430.43M | $279.53M | $220.85M |
| Total Stockholders Equity | $133.58M | $43.50M | $58.06M | $52.38M | $75.47M |
| Total Equity | $133.58M | $43.50M | $58.06M | $52.38M | $75.47M |
| Total Liabilities and Stockholders Equity | $180.77M | $307.89M | $290.88M | $150.45M | $143.74M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $180.77M | $307.89M | $290.88M | $150.45M | $143.74M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $8.05M | $210.14M | $202.07M | $70.47M | $37.45M |
| Net Debt | $-144.55M | $-67.78M | $-71.80M | $-60.83M | $-91.21M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $152.60M | $196.33M | $226.86M | $252.48M | $277.92M | $337.33M | $192.49M | $234.25M | $273.87M | $146.07M | $176.38M | $143.47M | $131.30M | $112.70M | $125.73M | $107.99M | $128.66M | $127.67M | $5.63M | $428.00K |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $152.60M | $196.33M | $226.86M | $252.48M | $277.92M | $337.33M | $192.49M | $234.25M | $273.87M | $146.07M | $176.38M | $143.47M | $131.30M | $112.70M | $125.73M | $107.99M | $128.66M | $127.67M | $5.63M | $428.00K |
| Net Receivables | $420.00K | $455.00K | $1.39M | $3.04M | $778.00K | $331.00K | $327.00K | $304.00K | $257.00K | $315.00K | $284.00K | $433.00K | $878.00K | $503.00K | $528.00K | $357.00K | $615.00K | $964.00K | $122.00K | $- |
| Inventory | $- | $- | $- | $- | $- | $-331.00K | $10.18M | $-304.00K | $-257.00K | $-315.00K | $1 | $5.90M | $-878.00K | $5.08M | $4.40M | $4.38M | $-129.28M | $-964.00K | $2.75M | $- |
| Other Current Assets | $7.38M | $10.66M | $13.81M | $12.84M | $16.66M | $25.97M | $324.00K | $9.52M | $6.63M | $7.68M | $4.95M | $600.00K | $7.81M | $747.00K | $621.00K | $679.00K | $132.17M | $4.18M | $296.00K | $2.93M |
| Total Current Assets | $160.40M | $207.45M | $242.06M | $274.54M | $295.36M | $363.30M | $203.32M | $243.78M | $280.49M | $153.75M | $181.62M | $150.40M | $139.11M | $119.03M | $131.28M | $113.40M | $132.17M | $131.85M | $8.80M | $3.36M |
| Property Plant Equipment Net | $13.54M | $8.40M | $9.62M | $9.45M | $9.37M | $6.27M | $6.68M | $6.78M | $7.22M | $7.93M | $8.42M | $8.93M | $9.49M | $9.90M | $10.36M | $10.86M | $11.32M | $11.46M | $11.73M | $11.91M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.83M | $6.71M | $6.75M | $4.59M | $3.16M | $3.16M | $3.16M | $3.16M | $3.16M | $3.16M | $3.16M | $1.85M | $1.85M | $245.00K | $245.00K | $245.00K | $245.00K | $245.00K | $771.00K | $295.00K |
| Total Non-Current Assets | $20.37M | $15.12M | $16.36M | $14.04M | $12.53M | $9.44M | $9.85M | $9.94M | $10.38M | $11.10M | $11.59M | $10.78M | $11.34M | $10.15M | $10.61M | $11.10M | $11.57M | $11.70M | $12.50M | $12.21M |
| Other Assets | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $180.77M | $222.56M | $258.42M | $288.58M | $307.89M | $372.73M | $213.17M | $253.72M | $290.88M | $164.85M | $193.21M | $161.18M | $150.45M | $129.18M | $141.89M | $124.50M | $143.74M | $143.55M | $21.30M | $15.56M |
| Account Payables | $9.24M | $12.37M | $13.02M | $12.37M | $10.95M | $7.86M | $9.70M | $10.92M | $8.33M | $8.57M | $9.25M | $7.89M | $9.12M | $12.43M | $9.86M | $14.29M | $13.46M | $15.19M | $8.91M | $9.39M |
| Short Term Debt | $1.59M | $1.83M | $4.34M | $7.87M | $2.06M | $2.01M | $1.96M | $1.91M | $1.86M | $1.81M | $1.76M | $1.72M | $1.67M | $1.63M | $1.59M | $1.54M | $1.50M | $9.82M | $1.42M | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-9.87M | $119.00K | $149.00K | $166.00K | $440.00K | $717.00K | $1.23M | $2.03M | $2.77M | $3.24M | $4.08M | $3.08M | $5.18M | $3.72M | $- |
| Other Current Liabilities | $29.89M | $29.89M | $21.69M | $51.64M | $43.30M | $35.77M | $19.55M | $19.67M | $17.22M | $14.61M | $12.47M | $9.27M | $9.62M | $8.33M | $6.98M | $7.94M | $13.36M | $2.68M | $15.72M | $15.85M |
| Total Current Liabilities | $40.73M | $44.09M | $39.05M | $71.87M | $56.31M | $35.77M | $31.33M | $32.64M | $27.58M | $25.43M | $24.20M | $20.11M | $22.45M | $25.15M | $21.67M | $27.85M | $31.40M | $32.86M | $29.77M | $25.24M |
| Long Term Debt | $6.45M | $- | $- | $205.14M | $206.97M | $205.72M | $206.65M | $203.26M | $202.07M | $170.82M | $173.93M | $113.73M | $70.47M | $75.54M | $75.57M | $35.75M | $35.95M | $11.70M | $9.36M | $39.74M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $110.00K | $110.00K | $150.00K | $130.00K | $737.00K | $170.00K | $1.41M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-110.00K | $- | $- | $- | $- | $-170.00K | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $1.11M | $1.65M | $- | $2.68M | $3.17M | $3.66M | $- | $- | $5.14M | $180.00K | $180.00K | $180.00K | $180.00K | $7.27M | $3.00K | $3.65M |
| Total Non-Current Liabilities | $6.45M | $- | $- | $205.14M | $208.08M | $207.37M | $206.65M | $205.94M | $205.24M | $174.48M | $173.93M | $113.73M | $75.61M | $75.83M | $75.90M | $36.06M | $36.87M | $18.96M | $10.77M | $43.39M |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $47.18M | $44.09M | $39.05M | $277.01M | $264.39M | $243.14M | $237.98M | $238.58M | $232.82M | $199.90M | $198.13M | $133.83M | $98.07M | $100.98M | $97.57M | $63.91M | $68.27M | $51.83M | $40.55M | $68.63M |
| Preferred Stock | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $143.55M | $- | $59.51M |
| Common Stock | $1.00K | $1.00K | $1.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K |
| Retained Earnings | $-106.13M | $-58.27M | $-14.40M | $-692.44M | $-613.73M | $-520.13M | $-468.34M | $-421.29M | $-372.37M | $-331.46M | $-296.13M | $-258.40M | $-227.15M | $-205.96M | $-185.38M | $-164.67M | $-145.38M | $-127.73M | $-109.55M | $-89.35M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $-143.55M | $-2.85M | $-23.23M |
| Other Total Stockholders Equity | $239.72M | $236.73M | $233.77M | $704.01M | $657.23M | $649.72M | $443.52M | $436.42M | $430.43M | $296.40M | $291.21M | $285.75M | $279.53M | $234.15M | $229.69M | $225.26M | $220.85M | $219.46M | $93.15M | $- |
| Total Stockholders Equity | $133.58M | $178.47M | $219.37M | $11.57M | $43.50M | $129.59M | $-24.81M | $15.13M | $58.06M | $-35.05M | $-4.92M | $27.35M | $52.38M | $28.20M | $44.32M | $60.59M | $75.47M | $91.73M | $-19.24M | $-53.07M |
| Total Equity | $133.58M | $178.47M | $219.37M | $11.57M | $43.50M | $129.59M | $-24.81M | $15.13M | $58.06M | $-35.05M | $-4.92M | $27.35M | $- | $- | $- | $- | $- | $- | $- | $-53.07M |
| Total Liabilities and Stockholders Equity | $180.77M | $222.56M | $258.42M | $288.58M | $307.89M | $372.73M | $213.17M | $253.72M | $290.88M | $164.85M | $193.21M | $161.18M | $150.45M | $129.18M | $141.89M | $124.50M | $143.74M | $143.55M | $21.30M | $15.56M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $180.77M | $222.56M | $258.42M | $288.58M | $307.89M | $372.73M | $213.17M | $253.72M | $290.88M | $164.85M | $193.21M | $161.18M | $150.45M | $129.18M | $141.89M | $124.50M | $143.74M | $143.55M | $21.30M | $15.56M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $8.05M | $1.83M | $2.17M | $210.89M | $210.14M | $205.72M | $208.61M | $203.26M | $202.07M | $172.63M | $175.70M | $115.45M | $70.47M | $77.17M | $77.15M | $37.30M | $37.45M | $11.70M | $10.78M | $39.74M |
| Net Debt | $-144.55M | $-194.50M | $-224.69M | $-41.59M | $-67.78M | $-131.61M | $16.12M | $-30.99M | $-71.80M | $26.56M | $-689.00K | $-28.02M | $-60.83M | $-35.54M | $-48.58M | $-70.69M | $-91.21M | $-115.97M | $5.15M | $39.31M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $1.69B | $-239.73M | $-145.23M | $-81.77M | $-76.12M |
| Depreciation and Amortization | $2.29M | $1.19M | $1.23M | $1.20M | $1.02M |
| Deferred Income Tax | $- | $- | $- | $-9.00K | $-2.14M |
| Stock Based Compensation | $58.52M | $24.85M | $17.79M | $15.05M | $5.02M |
| Change in Working Capital | $52.05M | $15.35M | $3.16M | $-17.52M | $12.69M |
| Accounts Receivables | $381.00K | $-521.00K | $130.00K | $-167.00K | $117.00K |
| Inventory | $- | $- | $- | $-11.03M | $7.76M |
| Accounts Payables | $17.90M | $2.11M | $-705.00K | $-4.64M | $10.43M |
| Other Working Capital | $33.77M | $13.76M | $3.74M | $-1.67M | $-5.61M |
| Other Non Cash Items | $-1.99B | $5.03M | $5.09M | $2.73M | $11.56M |
| Net Cash Provided by Operating Activities | $-194.41M | $-193.31M | $-115.30M | $-80.32M | $-47.97M |
| Investments in Property Plant and Equipment | $-2.60M | $-4.59M | $-686.00K | $-864.00K | $-1.36M |
| Acquisitions Net | $- | $- | $- | $55.00K | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $55.00K | $- |
| Net Cash Used for Investing Activities | $-2.60M | $-4.59M | $-686.00K | $-809.00K | $-1.36M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $201.96M | $127.37M | $40.20M | $136.85M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $71.68M | $201.96M | $128.81M | $83.77M | $166.46M |
| Net Cash Used Provided by Financing Activities | $71.68M | $201.96M | $258.55M | $83.77M | $166.46M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-125.33M | $4.06M | $142.56M | $2.64M | $117.12M |
| Cash at End of Period | $152.60M | $277.92M | $273.87M | $131.30M | $128.66M |
| Cash at Beginning of Period | $277.92M | $273.87M | $131.30M | $128.66M | $11.54M |
| Operating Cash Flow | $-194.41M | $-193.31M | $-115.30M | $-80.32M | $-47.97M |
| Capital Expenditure | $-2.60M | $-4.59M | $-686.00K | $-864.00K | $-1.36M |
| Free Cash Flow | $-197.01M | $-197.90M | $-115.99M | $-81.19M | $-49.33M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-47.87M | $-14.43M | $1.83B | $-78.71M | $-93.60M | $-51.79M | $-47.05M | $-48.92M | $-40.91M | $-35.33M | $-37.73M | $-31.25M | $-21.19M | $-20.58M | $-20.71M | $-19.29M | $-17.65M | $-20.50M | $-17.89M | $-20.09M |
| Depreciation and Amortization | $689.00K | $761.00K | $475.00K | $360.00K | $298.00K | $304.00K | $294.00K | $295.00K | $302.00K | $309.00K | $307.00K | $307.00K | $307.00K | $299.00K | $298.00K | $291.00K | $265.00K | $249.00K | $249.00K | $256.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-4.56M | $1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $-9.00K | $- | $- | $511.00K | $-2.69M | $41.00K |
| Stock Based Compensation | $2.98M | $2.96M | $47.53M | $5.04M | $6.43M | $6.53M | $6.25M | $4.69M | $5.36M | $4.69M | $5.30M | $5.11M | $4.18M | $3.49M | $3.95M | $3.42M | $1.37M | $1.30M | $1.26M | $1.09M |
| Change in Working Capital | $4.00K | $-42.69M | $35.49M | $7.20M | $28.36M | $-10.97M | $-3.45M | $1.42M | $2.98M | $-1.95M | $4.14M | $-2.00M | $-6.71M | $2.34M | $-6.51M | $-6.63M | $125.00K | $-15.00K | $3.14M | $9.44M |
| Accounts Receivables | $707.00K | $932.00K | $1.00K | $-610.00K | $-447.00K | $-4.00K | $-23.00K | $-61.00K | $58.00K | $-31.00K | $134.00K | $-4.00K | $-129.00K | $97.00K | $-181.00K | $46.00K | $599.00K | $-676.00K | $-5.00K | $199.00K |
| Inventory | $- | $- | $- | $- | $11.11M | $-9.26M | $-1.85M | $- | $-58.00K | $31.00K | $- | $- | $-2.43M | $408.00K | $-1.28M | $-7.73M | $2.23M | $-4.99M | $6.70M | $3.81M |
| Accounts Payables | $-3.12M | $-450.00K | $17.42M | $4.05M | $2.91M | $-1.59M | $-1.54M | $2.33M | $19.00K | $-940.00K | $1.47M | $-1.26M | $-3.41M | $2.34M | $-4.23M | $660.00K | $-1.18M | $5.93M | $-626.00K | $6.30M |
| Other Working Capital | $2.42M | $-43.17M | $18.07M | $3.76M | $25.89M | $-119.00K | $-30.00K | $-855.00K | $2.96M | $-1.01M | $-511.00K | $-743.00K | $-735.00K | $-508.00K | $-818.00K | $387.00K | $-1.53M | $-274.00K | $-2.93M | $-872.00K |
| Other Non Cash Items | $470.00K | $23.11M | $-1.97B | $5.38M | $6.26M | $1.68M | $1.65M | $1.62M | $1.68M | $1.44M | $1.06M | $902.00K | $786.00K | $776.00K | $602.00K | $563.00K | $497.00K | $4.57M | $4.62M | $1.88M |
| Net Cash Provided by Operating Activities | $-43.72M | $-30.28M | $-57.36M | $-63.05M | $-56.82M | $-54.24M | $-42.30M | $-39.94M | $-30.60M | $-30.84M | $-26.92M | $-26.94M | $-22.62M | $-13.68M | $-22.38M | $-21.65M | $-15.39M | $-13.88M | $-11.31M | $-7.39M |
| Investments in Property Plant and Equipment | $-16.00K | $-247.00K | $-1.22M | $-1.12M | $-3.44M | $-811.00K | $-317.00K | $-23.00K | $-267.00K | $20.00K | $-322.00K | $-117.00K | $-267.00K | $-169.00K | $-414.00K | $-14.00K | $-612.00K | $-299.00K | $-362.00K | $-91.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $55.00K | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-16.00K | $-247.00K | $-1.22M | $-1.12M | $-3.44M | $-811.00K | $-317.00K | $-23.00K | $-267.00K | $20.00K | $-322.00K | $-117.00K | $-267.00K | $-169.00K | $-359.00K | $-14.00K | $-612.00K | $-299.00K | $-362.00K | $-91.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-71.68M | $32.95M | $38.73M | $860.00K | $199.89M | $854.00K | $356.00K | $2.76M | $506.00K | $- | $- | $40.20M | $- | $- | $- | $27.00K | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $2.71M | $-2.71M | $38.73M | $860.00K | $199.89M | $854.00K | $356.00K | $158.66M | $506.00K | $60.16M | $39.22M | $41.48M | $820.00K | $40.48M | $988.00K | $17.00M | $136.22M | $16.88M | $-3.63M |
| Net Cash Used Provided by Financing Activities | $- | $2.71M | $30.25M | $38.73M | $860.00K | $199.89M | $854.00K | $356.00K | $158.66M | $506.00K | $60.16M | $39.22M | $41.48M | $820.00K | $40.48M | $988.00K | $17.00M | $136.22M | $16.88M | $-3.63M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $102.46M | $-144.53M | $42.07M | $- | $- | $- | $- | $- | $-41.48M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-43.74M | $-30.53M | $-25.62M | $-25.44M | $-59.40M | $144.84M | $-41.76M | $-39.61M | $127.79M | $-30.31M | $32.92M | $12.17M | $18.60M | $-13.02M | $17.74M | $-20.67M | $995.00K | $122.04M | $5.20M | $-11.11M |
| Cash at End of Period | $152.60M | $196.33M | $226.86M | $252.48M | $277.92M | $337.33M | $192.49M | $234.25M | $273.87M | $146.07M | $176.38M | $143.47M | $131.30M | $112.70M | $125.73M | $107.99M | $128.66M | $127.67M | $5.63M | $428.00K |
| Cash at Beginning of Period | $196.33M | $226.86M | $252.48M | $277.92M | $337.33M | $192.49M | $234.25M | $273.87M | $146.07M | $176.38M | $143.47M | $131.30M | $112.70M | $125.73M | $107.99M | $128.66M | $127.67M | $5.63M | $428.00K | $11.54M |
| Operating Cash Flow | $-43.72M | $-30.28M | $-57.36M | $-63.05M | $-56.82M | $-54.24M | $-42.30M | $-39.94M | $-30.60M | $-30.84M | $-26.92M | $-26.94M | $-22.62M | $-13.68M | $-22.38M | $-21.65M | $-15.39M | $-13.88M | $-11.31M | $-7.39M |
| Capital Expenditure | $-16.00K | $-247.00K | $-1.22M | $-1.12M | $-3.44M | $-811.00K | $-317.00K | $-23.00K | $-267.00K | $20.00K | $-322.00K | $-117.00K | $-267.00K | $-169.00K | $-414.00K | $-14.00K | $-612.00K | $-299.00K | $-362.00K | $-91.00K |
| Free Cash Flow | $-43.74M | $-30.53M | $-58.57M | $-64.17M | $-60.26M | $-55.06M | $-42.62M | $-39.97M | $-30.87M | $-30.82M | $-27.24M | $-27.06M | $-22.89M | $-13.84M | $-22.79M | $-21.66M | $-16.00M | $-14.18M | $-11.67M | $-7.48M |
Inhibrx Biosciences Dividends
Explore Inhibrx Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-74.86x
Inhibrx Biosciences Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.85 | $0.85 | May 30, 2024 | May 30, 2024 | June 20, 2024 |
Inhibrx Biosciences News
Read the latest news about Inhibrx Biosciences, including recent articles, headlines, and updates.
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). These results were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Annual Cancers Symposium.
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders provided a five-year term loan facility for up to $150 million (the "Credit Facility"). "This enables us strategic flexibility post data readouts expected later this year for our INBRX-109 and INBRX-106 programs," said Kelly Deck, Chief Financial Officer of Inhibrx.
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025.
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research.
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a "when-issued" basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the "Merger") at the Company's special meeting of stockholders, which will be held on May 24, 2024. As a result, shares of SpinCo common stock are expected to begin trading on a "when-issued" basis on Nasdaq on May 28, 2024 (rather than May 16, 2024), under the symbol "INXB" and under "Inhibrx Biosciences, Inc." When-issued trading of shares of SpinCo common stock will continue until the distribution of shares of SpinCo common stock in the Spin-Off occurs.
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will.
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p.m.
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights Sale of INBRX-101 to Sanofi: In January 2024, the Company announced that it entered into a definitive agreement with Aventis, Inc. ("Aventis"), a subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all of the assets and liabilities associated with INBRX-101 ("the Merger").
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/case/inhibrx-inc or call Guri Ademi toll-free at 866-264-3995.
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to treat rare diseases.
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms of the proposed transaction, for each Inhibrx share, Inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets. Halp.
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx's outstanding debt balance and capitalize New Inhibrx with $200 million in cash SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation (a subsidiary of Sanofi) will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the merger, all non-101 assets and liabilities, including INBRX-105, INBRX-106, INBRX-109, Inhibrx's non-101 discovery pipeline and its corporate infrastructure, will be spun out from the Company into a new publicly traded company, Inhibrx Biosciences, Inc. ("New Inhibrx").
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide (IRI/TMZ) for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Inhibrx presented this dataset as of the data cut of September 8 th, 2023 at the Annual Connective Tissue Oncology Society (CTOS) Conference today.
Inhibrx Announces Participation in Upcoming Scientific Conferences
SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences: Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting November 1 st – 4th, 2023 – Dublin, Ireland Title: The Tetravalent Death Receptor 5 Agonist INBRX-109 Combined With Chemotherapy in Ewing Sarcoma: Preliminary Data From A Phase 1 StudyLead Author: Rashmi Chugh, MDPoster presentation on Thursday, November 2 nd, 2023 from 5:30 PM – 6:30 PM Irish Standard TimeLocation: The Liffey Convention Centre in Dublin, Ireland Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting November 3 rd – 5th, 2023 – San Diego, California Title: Phase 1/2 Study of the Bispecific 4-1BB and PD-L1 Antibody INBRX-105 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Jong Chul Park, MDAbstract: 742Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center, San Diego, CA - Hall A Presentation Title: Phase 1/2 Study of the Hexavalent OX40 Agonist INBRX-106 Alone and in Combination With Pembrolizumab in Select Solid TumorsLead Author: Rachel E. Sanborn, MDAbstract: 748Trial-in-progress poster presentation on Saturday, November 4 th, 2023 from 9 AM – 8:30 PM Pacific Standard Time Location: San Diego Convention Center in San Diego, CA - Hall A The posters will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations upon commencement of each respective presentation.
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD").
Inhibrx Announces $200 Million Private Placement Financing
SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX.
Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much
INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fast Track designation from the FDA for the treatment of emphysema.
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2023 and provided an update on recent corporate highlights. Recent Corporate Highlights On May 30, 2023, Inhibrx announced that the U.S. Food and Drug Administration granted Fast Track designation to INBRX-101, an optimized recombinant human AAT-Fc fusion protein, for the treatment of patients with emphysema due to alpha-1 antitrypsin deficiency, or AATD.
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arbitration hearing as a way of surreptitiously getting a look at its proprietary research.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for INBX.